Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene

PR NewswireDec 30, 2024 19:00 ET

The Hang Seng Index fluctuates around the 20,000-point mark, and short-term new stocks are seeing a return of profit-making effects ｜ A barometer of Hong Kong stocks.

① The Hang Seng Index is fluctuating around the 20,000 point mark, what hot topics is the market focusing on? ② The return of short-term new stock profitability effects, what impact does it have?

cls.cnDec 30, 2024 07:44 ET

Open Source Securities: DLL3 is a star target with high expression in SCLC, and various domestic new drugs can be expected in the future.

DLL3 is highly expressed in 80% of SCLC patients, providing a better solution for targeted therapy. Currently, only one product targeting this point has been approved for market, resulting in a favorable competitive landscape.

Zhitong FinanceDec 29, 2024 21:50 ET

BEIGENE (06160.HK) issued 0.1032 million shares due to the vesting of restricted stock units.

On December 30th, Gelonghui announced that BEIGENE (06160.HK) will issue 0.1032 million ordinary shares on December 29, 2024, due to the vesting of restricted stock units granted under the equity plan (excluding company directors).

Gelonghui FinanceDec 29, 2024 19:05 ET

The Market Doesn't Like What It Sees From BeiGene, Ltd.'s (NASDAQ:BGNE) Revenues Yet

Simply Wall StDec 29, 2024 09:08 ET

Seize the innovative leading value and explore the investment opportunities in Hong Kong stocks in the pharmaceutical sector after the deep pullback.

Since the beginning of this year, in the pharmaceuticals Sector, the Hong Kong stock market has demonstrated more cost-effective investment value compared to the A-shares.

Zhitong FinanceDec 28, 2024 06:34 ET